Heparin-Induced Thrombocytopenia

Quick Answer

Heparin-induced thrombocytopenia (HIT) is an immune-mediated prothrombotic disorder caused by antibodies against platelet factor 4 (PF4)/heparin complexes. Despite the name suggesting bleeding risk from thrombocytopenia, HIT is paradoxically a hypercoagulable state with high risk of life-threatening arterial and venous thrombosis. [1,2]

Definition criteria (any of the following):

• Platelet count drop ≥50% from baseline (even if nadir remains within normal range)
• New thrombosis occurring 5-14 days after heparin exposure
• Platelet recovery after heparin cessation with alternative anticoagulation

Type I vs Type II HIT:

• Type I (non-immune): Benign, transient, non-immune platelet drop within 1-4 days of heparin initiation; no clinical significance; heparin can be continued
• Type II (immune-mediated): Clinically significant; onset 5-14 days after heparin exposure (or earlier with prior heparin exposure within 100 days); requires immediate cessation of ALL heparin and alternative anticoagulation [1,3]

4Ts Score (pretest probability assessment) [4]:

• Thrombocytopenia: magnitude and nadir
• Timing: onset relative to heparin exposure
• Thrombosis: new thrombosis or other sequelae
• oTher causes: exclusion of other causes of thrombocytopenia
• Score ≥6 = High probability; 4-5 = Intermediate; ≤3 = Low probability

Immediate Management:

1. STOP ALL HEPARIN (including flushes, heparin-coated catheters, LMWH)
2. Start alternative anticoagulant: Argatroban (hepatic clearance), Bivalirudin (proteolytic clearance), or Fondaparinux (renal clearance)
3. Do NOT give warfarin acutely (causes venous limb gangrene from protein C depletion)
4. Do NOT give platelets unless life-threatening bleeding (may fuel thrombosis)
5. Screen for occult thrombosis (Doppler lower limbs) [1,2,5]

---

CICM Exam Focus

Key High-Yield Points

1. Pathophysiology: Anti-PF4/heparin IgG antibodies → platelet FcγRIIa receptor binding → massive platelet activation → thrombosis AND thrombocytopenia [1,6]
2. 4Ts Score validation: Score ≤3 has NPV greater than 99% for ruling out HIT; score ≥6 has PPV ~60% [4,7]
3. Timing of onset: Classic 5-14 days; rapid-onset HIT within 24 hours if heparin exposure within past 100 days [1,8]
4. Thrombosis risk: 25-50% of untreated HIT patients develop thrombosis; VTE more common than arterial [9]
5. Diagnosis: ELISA (high sensitivity ~97%, lower specificity ~75%); SRA is gold standard (specificity greater than 95%) [10,11]
6. ELISA OD cutoff: OD ≥2.0 correlates with functional assay positivity; OD below 0.4 essentially excludes HIT [12]
7. Argatroban dosing in ICU: Start 0.5-1.0 mcg/kg/min (NOT package insert 2 mcg/kg/min); target aPTT 1.5-3x baseline [13,14]
8. Warfarin timing: Only initiate after platelet recovery to greater than 150 x 10⁹/L; overlap with DTI for minimum 5 days [15]
9. DOAC transition: Rivaroxaban and apixaban are effective alternatives during HIT recovery [16,17]
10. Duration of anticoagulation: Minimum 4 weeks if no thrombosis; 3-6 months if thrombosis present [5,18]

Common Viva Themes

• Differentiate Type I vs Type II HIT; mechanism of antibody-mediated platelet activation
• Calculate and interpret 4Ts score in clinical scenario
• Choose alternative anticoagulant based on organ dysfunction (hepatic vs renal failure)
• Explain why warfarin is contraindicated acutely in HIT (protein C/S depletion → venous limb gangrene)
• Discuss diagnostic testing: when to use ELISA vs SRA, interpretation of optical density
• Management of HIT in specific scenarios: cardiac surgery, ECMO, renal replacement therapy
• Approach to "suspected HIT" while awaiting confirmatory testing

Common Pitfalls

• Failing to consider HIT when platelet drop is to within "normal" range (relative drop is key)
• Using LMWH as alternative to UFH (5-10% cross-reactivity with HIT antibodies) [19]
• Starting warfarin before platelet recovery (causes venous limb gangrene) [20]
• Not stopping ALL heparin sources (flushes, heparin-coated catheters, dialysis circuits)
• Transfusing platelets in non-bleeding patient (may fuel thrombosis) [1]
• Using standard argatroban dosing in critically ill patients (hepatic congestion prolongs half-life) [13]
• Assuming negative ELISA excludes HIT (timing of testing matters; may be falsely negative early)
• Forgetting to screen for occult thrombosis in all confirmed HIT patients

---

Key Points

• HIT Type II is immune-mediated; anti-PF4/heparin IgG activates platelets via FcγRIIa receptor [1,6]
• 4Ts score: Thrombocytopenia, Timing, Thrombosis, oTher causes; ≤3 low probability (NPV greater than 99%) [4]
• Platelet drop ≥50% from baseline is key criterion, even if nadir remains in normal range [1]
• Classic timing 5-14 days; rapid-onset (below 24h) with prior heparin exposure within 100 days [8]
• 25-50% develop thrombosis if untreated; VTE more common than arterial thrombosis [9]
• ELISA highly sensitive (~97%); SRA is gold standard for specificity (~95%) [10,11]
• STOP ALL heparin immediately upon clinical suspicion; start alternative anticoagulant [2]
• Argatroban: hepatic clearance; start 0.5-1.0 mcg/kg/min in ICU (reduced from package insert) [13,14]
• Bivalirudin: proteolytic clearance (80%); preferred in hepatic dysfunction [21]
• Fondaparinux: renal clearance; not for CrCl below 30 mL/min; no monitoring required [22]
• NEVER start warfarin acutely; causes protein C depletion → venous limb gangrene [20]
• Warfarin only after platelet recovery greater than 150 x 10⁹/L; overlap DTI minimum 5 days [15]
• DOACs (rivaroxaban, apixaban) safe and effective for transition [16,17]
• Anticoagulation duration: 4 weeks (no thrombosis), 3-6 months (with thrombosis) [5,18]

---

Definition and Classification

What is Heparin-Induced Thrombocytopenia?

Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction to heparin that paradoxically causes a prothrombotic state despite thrombocytopenia. It is one of the most important non-bleeding complications of heparin therapy and is associated with significant morbidity and mortality if not recognized and treated promptly. [1,2]

HIT is defined by the development of thrombocytopenia (platelet count drop ≥50% from baseline) typically occurring 5-14 days after initiation of heparin therapy, or earlier in patients with prior heparin exposure within the past 100 days. The thrombocytopenia is caused by immune-mediated platelet activation and consumption, while the prothrombotic state results from the same immune complexes activating the coagulation cascade. [1,3]

Type I HIT (Non-Immune, Benign)

Type I HIT is a non-immune phenomenon characterized by:

• Mild, transient platelet decrease (rarely below 100 x 10⁹/L)
• Onset within 1-4 days of heparin initiation
• Due to direct platelet aggregation by heparin
• No thrombotic complications
• Self-limiting; resolves spontaneously even with continued heparin
• No clinical significance; does not require treatment or heparin cessation

Type I HIT affects up to 10-30% of patients receiving heparin and represents a minor, transient pharmacological effect rather than a pathological immune response. [3,23]

Type II HIT (Immune-Mediated, Clinically Significant)

Type II HIT is the clinically significant form caused by IgG antibodies against platelet factor 4 (PF4)/heparin complexes. Key features include:

• Platelet count drop ≥50% from baseline (or new thrombosis 5-14 days after heparin)
• Typical onset 5-14 days after heparin exposure
• Rapid-onset variant (below 24 hours) if prior heparin exposure within 100 days
• High risk of thrombosis (25-50% if untreated)
• Requires immediate heparin cessation and alternative anticoagulation
• Associated with significant morbidity (limb loss, stroke, PE) and mortality (10-30%)

Throughout this document, "HIT" refers to Type II HIT unless otherwise specified. [1,2,9]

Diagnostic Criteria

The diagnosis of HIT is based on clinical assessment combined with laboratory testing:

Clinical Criteria:

1. Thrombocytopenia: Platelet count drop ≥50% from baseline (even if nadir remains within normal range)
2. Timing: Onset 5-14 days after heparin exposure (or below 24 hours with prior recent exposure)
3. Thrombosis: New arterial or venous thrombosis in association with platelet drop
4. Exclusion of other causes: DIC, sepsis, drug-induced thrombocytopenia, TTP/HUS
5. Platelet recovery: Count recovers after heparin cessation and alternative anticoagulation

Laboratory Criteria:

1. Positive immunoassay (ELISA) for anti-PF4/heparin antibodies AND/OR
2. Positive functional assay (serotonin release assay or heparin-induced platelet activation assay)

A combination of clinical probability assessment (4Ts score) and laboratory testing is required for definitive diagnosis. [1,4,10]

---

Epidemiology

Incidence and Risk Factors

The incidence of HIT varies significantly based on patient population, type of heparin used, and duration of exposure:

Overall incidence by heparin type [24,25]:

• Unfractionated heparin (UFH): 1-5%
• Low molecular weight heparin (LMWH): 0.1-1%
• Fondaparinux: below 0.1% (rare case reports)

Incidence by clinical setting [9,24]:

Risk factors for HIT development [1,9,24]:

• Heparin type: UFH > LMWH > Fondaparinux
• Duration of exposure: greater than 5 days increases risk
• Prior heparin exposure: Within 100 days; sensitization to PF4/heparin
• Patient population: Surgical > medical; cardiac/orthopedic highest risk
• Sex: Female > Male (relative risk 1.5-2.0)
• Severity of illness: Trauma, sepsis increase antibody formation
• Inflammatory state: Postoperative, infection increases PF4 release

Risk factors for thrombosis in HIT [9,26]:

• Magnitude of platelet count drop
• Delay in diagnosis and treatment
• Continued heparin exposure
• Inadequate anticoagulation
• Underlying malignancy
• Prior history of thrombosis
• Central venous catheter presence

Thrombotic Complications

Thrombosis is the hallmark complication of HIT and occurs in 25-50% of untreated patients:

Distribution of thrombosis [1,9]:

• Venous thromboembolism (VTE): 50-60% of thrombotic events
  • Deep vein thrombosis (most common)
  • Pulmonary embolism (15-25% of HIT patients)
  • Adrenal vein thrombosis (adrenal hemorrhagic infarction)
  • Cerebral venous sinus thrombosis
• Arterial thrombosis: 30-40% of thrombotic events
  • Lower limb arterial occlusion
  • Stroke
  • Myocardial infarction
  • Mesenteric ischemia

Mortality and morbidity [2,9,27]:

• Mortality: 10-30% (primarily from PE, stroke, or limb ischemia)
• Limb amputation: 10-20% of patients with lower limb thrombosis
• Residual disability: 20-30% of survivors

Special Populations

Cardiac surgery patients: High-risk population due to large heparin boluses during cardiopulmonary bypass. Anti-PF4/heparin antibody seroconversion occurs in up to 50-70%, but clinically significant HIT develops in only 1-3%. Distinguishing HIT from other causes of postoperative thrombocytopenia (dilution, consumption, sepsis) is challenging. [28]

ECMO patients: Prolonged heparin exposure increases HIT risk. Management complicated by need for anticoagulation of the circuit. Argatroban and bivalirudin are preferred alternatives. [29]

Renal replacement therapy patients: Chronic heparin exposure with each dialysis session increases sensitization risk. Fondaparinux contraindicated in ESRD; argatroban preferred. [13,30]

---

Pathophysiology

The PF4-Heparin Immune Complex

The pathogenesis of HIT involves a complex interplay between platelets, endothelium, and the immune system, centered on the formation of immunogenic PF4/heparin complexes:

Step 1: PF4 Release

• Platelet factor 4 (PF4) is a positively charged chemokine stored in platelet alpha-granules
• Released when platelets are activated (even minimal activation from venipuncture, surgery, inflammation)
• Normal physiological role: neutralization of heparin-like glycosaminoglycans on endothelium
• PF4 concentration increases significantly in inflammatory states [1,6]

Step 2: PF4-Heparin Complex Formation

• Heparin (negatively charged polysaccharide) binds to PF4 with high affinity
• Optimal stoichiometry: approximately 1:1 molar ratio forms ultra-large multimolecular complexes (ULCs)
• Complex size matters: only large complexes are sufficiently immunogenic
• UFH forms larger complexes than LMWH (explains higher HIT incidence with UFH)
• Fondaparinux forms minimal complexes (very low HIT risk) [6,31]

Step 3: Neoantigen Exposure and Antibody Formation

• PF4-heparin binding induces conformational change in PF4
• This exposes cryptic epitopes (neoantigens) not present on PF4 alone
• The immune system recognizes these neoantigens as foreign
• B cells produce IgG antibodies against the PF4/heparin complex
• Antibody formation typically begins 5-10 days after heparin exposure [1,6]

Platelet Activation Cascade

Step 4: Immune Complex-Platelet Binding

• Anti-PF4/heparin IgG antibodies bind to PF4/heparin complexes on platelet surface
• The Fc portion of IgG binds to FcγRIIa receptors on adjacent platelets
• FcγRIIa is a low-affinity IgG receptor present on platelets, monocytes, and neutrophils
• Cross-linking of FcγRIIa triggers intracellular signaling cascades [6,32]

Step 5: Platelet Activation and Procoagulant Response

• FcγRIIa activation causes:
  • Platelet degranulation (release of more PF4 → positive feedback loop)
  • Phosphatidylserine exposure on platelet surface
  • Release of procoagulant microparticles
  • Thromboxane A2 generation
  • Platelet aggregation and consumption [1,6]

Step 6: Thrombin Generation

• Procoagulant microparticles provide phospholipid surface for coagulation
• Massive thrombin generation (up to 30-fold increase)
• Thrombin activates more platelets, cleaves fibrinogen, and activates factors V, VIII, XI
• Results in explosive coagulation activation despite thrombocytopenia [33]

Endothelial and Monocyte Involvement

Beyond platelets, HIT antibodies also target other cells expressing PF4 on their surface:

Endothelial cells:

• PF4 binds to heparan sulfate proteoglycans on endothelial surface
• Anti-PF4/heparin antibodies bind to this complex
• Causes endothelial activation and tissue factor expression
• Direct vascular injury promotes thrombosis
• May explain predilection for certain vascular beds (especially microcirculation) [34]

Monocytes:

• Express FcγRIIa receptors
• Immune complex binding activates monocytes
• Tissue factor expression on monocyte surface
• Contributes to systemic hypercoagulability
• Cytokine release amplifies inflammatory response [6,35]

Why Thrombocytopenia AND Thrombosis?

The apparent paradox of simultaneous thrombocytopenia and thrombosis is explained by the mechanism:

Thrombocytopenia results from:

• Platelet consumption by activated clotting
• Clearance of antibody-coated platelets by splenic macrophages
• Platelet sequestration in microthrombi

Thrombosis results from:

• Massive platelet activation (released platelet contents are prothrombotic)
• Thrombin generation from procoagulant microparticles
• Endothelial activation and tissue factor expression
• Monocyte tissue factor expression

The platelet count drop reflects the intensity of the prothrombotic process rather than a bleeding tendency. More profound thrombocytopenia generally indicates higher thrombotic risk. [1,33]

Immunological Memory

"Delayed-onset HIT": Thrombocytopenia and thrombosis occurring 5-40 days after heparin cessation due to persistent circulating antibodies. [36]

"Rapid-onset HIT": Occurs within 24 hours of heparin re-exposure in patients with pre-existing antibodies from heparin exposure within the past 100 days. Anti-PF4/heparin antibodies typically decline over 50-85 days but can persist up to 100 days or longer. [8]

Autoimmune HIT: Rare variant where antibodies activate platelets independently of heparin. May present after heparin cessation or without any heparin exposure (seen in vaccine-induced immune thrombocytopenia and thrombosis - VITT). [37]

---

Clinical Presentation

Thrombocytopenia

The hallmark of HIT is a significant decrease in platelet count:

Magnitude and timing [1,4]:

• Typical drop: ≥50% from baseline (mean drop ~60%)
• Absolute nadir: Usually 20-100 x 10⁹/L
  • Rarely below 10 x 10⁹/L (if below 10, consider other diagnoses)
  • Can remain in "normal" range if baseline was high
• Timing of onset:
  • "Classic: Day 5-14 after heparin initiation"
  • "Rapid-onset: Within 24 hours (prior heparin exposure in last 100 days)"
  • "Delayed-onset: Days to weeks after heparin stopped"

Key point: A relative drop of ≥50% is more important than the absolute platelet count. A patient with baseline platelets of 400 x 10⁹/L who drops to 180 x 10⁹/L (still "normal") has a significant relative drop suspicious for HIT.

Thrombotic Manifestations

Thrombosis is the major clinical consequence of HIT and should be actively sought in all patients:

Venous thrombosis (more common) [1,9]:

• Deep vein thrombosis (lower > upper limb)
• Pulmonary embolism
• Cerebral venous sinus thrombosis
• Adrenal vein thrombosis (causes hemorrhagic adrenal infarction)
• Hepatic/portal vein thrombosis
• Upper extremity DVT (especially with central venous catheters)

Arterial thrombosis [1,9]:

• Limb ischemia (most common arterial manifestation)
• Stroke (especially in cardiac surgery patients)
• Myocardial infarction
• Mesenteric ischemia
• Aortic thrombosis (rare but devastating)

Microvascular thrombosis [9,27]:

• Skin necrosis at heparin injection sites
• Digital ischemia (fingers, toes)
• Venous limb gangrene (classically with warfarin co-administration)
• Purpura fulminans (rare)

Skin Manifestations

Skin lesions can be an early warning sign of HIT, sometimes appearing before significant platelet drop:

Injection site reactions [38]:

• Erythematous plaques or nodules at subcutaneous heparin injection sites
• Pain and tenderness
• May progress to skin necrosis
• Highly specific for HIT when present (positive predictive value ~80%)

Skin necrosis:

• Can occur at injection sites or distant sites
• Full-thickness necrosis requiring debridement
• May occur before systemic thrombocytopenia is evident

Venous Limb Gangrene

A catastrophic complication occurring when warfarin is initiated in the acute phase of HIT:

Mechanism [20]:

• Warfarin depletes vitamin K-dependent anticoagulants (protein C/S) before depleting procoagulant factors
• Protein C half-life (6-8 hours) << factor II half-life (60-72 hours)
• Creates transient hypercoagulable state during first few days of warfarin
• In the setting of HIT-induced thrombin generation, this tips balance toward microvascular thrombosis

Clinical presentation:

• Progressive, symmetric limb cyanosis
• Typically affects lower limbs
• INR often supratherapeutic (greater than 3.0) at onset
• May progress to irreversible gangrene requiring amputation

Prevention: NEVER initiate warfarin until platelet count has recovered to greater than 150 x 10⁹/L and patient is adequately anticoagulated with alternative agent.

Unusual Presentations

Delayed-onset HIT [36]:

• Thrombocytopenia and/or thrombosis occurring 5-40 days after heparin discontinuation
• Often presents after hospital discharge
• May be misdiagnosed as "new" VTE unrelated to prior heparin exposure

Fondaparinux-associated HIT [39]:

• Very rare (below 0.1%)
• Case reports exist; generally thought to be coincidental or represent autoimmune HIT
• Fondaparinux can be considered a safe alternative in most HIT cases

Cardiac surgery-associated HIT [28]:

• Diagnosis challenging due to multiple causes of postoperative thrombocytopenia
• May present as:
  • Progressive platelet count decrease from day 5
  • Graft occlusion
  • Stroke
  • Limb ischemia

---

Diagnostic Approach

Clinical Probability: The 4Ts Score

The 4Ts score is a validated clinical prediction tool for assessing the pretest probability of HIT. It should be calculated for all patients with suspected HIT before ordering laboratory tests. [4,7]

4Ts Scoring System:

Score Interpretation [4,7]:

Key points about 4Ts score:

• A score of ≤3 has very high negative predictive value (greater than 99%) and effectively rules out HIT
• A score of ≥6 should prompt immediate heparin cessation and alternative anticoagulation
• Intermediate scores (4-5) are the most challenging; empiric treatment while awaiting results is often appropriate
• The score performs best when applied by experienced clinicians
• Inter-rater variability is significant; structured application improves reliability [7]

Laboratory Testing

Immunoassays (Screening Tests)

PF4/Heparin ELISA [10,11]:

• Detects antibodies (IgG, IgA, IgM) against PF4/heparin complexes
• Sensitivity: 90-98% (excellent rule-out test)
• Specificity: 75-85% (many false positives)
• Turnaround time: 2-4 hours (if in-house); 24-48 hours (send-out)

Optical Density (OD) interpretation [12]:

Limitations of ELISA:

• Detects all antibody classes, but only IgG is clinically significant
• Cannot distinguish pathogenic from non-pathogenic antibodies
• High false-positive rate in cardiac surgery, inflammation
• OD thresholds vary between laboratories

IgG-specific ELISA: Higher specificity (~90-95%) than polyspecific ELISA; preferred if available [10]

Particle immunofiltration assays (PFA/PaGIA):

• Rapid point-of-care tests
• Lower sensitivity than ELISA (80-90%)
• Useful for quick screening; negative result requires confirmation

Functional Assays (Confirmatory Tests)

Functional assays detect platelet-activating antibodies and are the gold standard for HIT diagnosis:

Serotonin Release Assay (SRA) [10,11]:

• Gold standard; considered reference method
• Principle: Patient serum + ¹⁴C-serotonin-labeled donor platelets + heparin
• Positive: greater than 20% serotonin release at therapeutic heparin concentrations (0.1-0.3 IU/mL) with inhibition at supratherapeutic concentrations (100 IU/mL)
• Sensitivity: 90-95%
• Specificity: greater than 95%
• Limitations: Requires radioactive materials, technically demanding, limited availability, long turnaround time (days to weeks)

Heparin-Induced Platelet Activation Assay (HIPA) [10]:

• Uses visual assessment of platelet aggregation
• Similar performance to SRA
• Does not require radioactivity
• Still technically demanding; limited availability

Particle Gel Immunoassay (ID-H/PF4-PaGIA):

• Rapid functional-like test
• Lower sensitivity than SRA
• Available in some centers

Diagnostic Algorithm

Step 1: Calculate 4Ts score for all patients with suspected HIT

Step 2: Based on 4Ts score:

• Score 0-3 (Low): HIT unlikely; do not test; investigate other causes
• Score 4-5 (Intermediate): Send immunoassay; consider empiric alternative anticoagulation
• Score 6-8 (High): Stop all heparin; start alternative anticoagulation; send immunoassay

Step 3: Interpret immunoassay result:

• Negative ELISA (OD below 0.4): HIT excluded; may resume heparin if clinically indicated
• Positive ELISA (OD ≥0.4): Proceed based on OD level:
  • "OD 0.4-2.0 with intermediate 4Ts: Request functional assay"
  • "OD ≥2.0: HIT highly likely; continue alternative anticoagulation; functional assay optional"

Step 4: If functional assay available:

• Positive SRA/HIPA: HIT confirmed
• Negative SRA/HIPA: HIT excluded (even with positive ELISA)

Screening for Thrombosis

All patients with confirmed or strongly suspected HIT should be screened for occult thrombosis:

Recommended imaging [5]:

• Bilateral lower extremity Doppler ultrasound (DVT screening)
• Consider upper extremity Doppler if central venous catheter present
• CT pulmonary angiography if any respiratory symptoms or unexplained hypoxia
• Additional imaging based on clinical suspicion

Screening identifies asymptomatic thrombosis in 25-50% of HIT patients and guides duration of anticoagulation therapy.

---

Management

Immediate Actions Upon Suspicion

When HIT is suspected (4Ts score ≥4), the following steps should be taken immediately [1,2,5]:

1. STOP ALL HEPARIN

• Discontinue UFH and LMWH (including prophylactic doses)
• Remove heparin-coated catheters if possible
• Stop heparin flushes for IV lines and arterial lines
• Communicate to all team members (nursing, pharmacy, dialysis)
• Alert blood bank (heparin-coated devices during transfusion)

2. START ALTERNATIVE ANTICOAGULATION

• All patients with suspected HIT need therapeutic anticoagulation (not prophylactic)
• The prothrombotic state persists even after heparin cessation
• Choice of agent based on organ function and clinical context

3. DO NOT TRANSFUSE PLATELETS

• Unless life-threatening bleeding is present
• Platelet transfusion may "fuel the fire" of thrombosis
• Exception: May be considered for urgent invasive procedures in consultation with hematology

4. DO NOT START WARFARIN

• Contraindicated until platelet count greater than 150 x 10⁹/L
• Risk of venous limb gangrene
• If already on warfarin, give vitamin K to reverse

5. ORDER DIAGNOSTIC TESTING

• ELISA and/or functional assay
• Doppler ultrasound of bilateral lower extremities

Alternative Anticoagulants

Argatroban

Argatroban is a direct thrombin inhibitor (DTI) and one of the two FDA-approved agents for HIT:

Pharmacology [13,14]:

• Mechanism: Reversible direct thrombin inhibitor
• Metabolism: Hepatic (primarily CYP3A4)
• Half-life: 45-52 minutes (prolonged in hepatic dysfunction)
• Monitoring: aPTT (target 1.5-3.0 x baseline)
• No antidote (short half-life allows rapid offset)

Dosing in critically ill patients [13,14]:

Key points:

• Package insert dose (2 mcg/kg/min) is usually too high for ICU patients
• Hepatic congestion from right heart failure prolongs half-life significantly
• Check aPTT every 2 hours initially; adjust dose in 0.25 mcg/kg/min increments
• Falsely elevates INR (complicates transition to warfarin)

Advantages: Hepatic clearance (safe in renal failure); extensive experience in ICU

Disadvantages: No reversal agent; falsely elevates INR; prolonged half-life in hepatic dysfunction

Bivalirudin

Bivalirudin is another direct thrombin inhibitor with unique metabolism:

Pharmacology [21]:

• Mechanism: Reversible direct thrombin inhibitor
• Metabolism: 80% proteolytic (non-enzymatic), 20% renal
• Half-life: 25 minutes (prolonged to 1-3 hours in renal failure)
• Monitoring: aPTT or ACT
• No antidote (very short half-life)

Dosing [21]:

Advantages: Hepatic failure (preferred agent); very short half-life (ideal for procedures); no INR interference

Disadvantages: Renal dose adjustment needed; off-label for HIT (FDA-approved for PCI); may require more frequent monitoring

Fondaparinux

Fondaparinux is a synthetic pentasaccharide that inhibits factor Xa:

Pharmacology [22]:

• Mechanism: Indirect factor Xa inhibitor (via antithrombin)
• Metabolism: Renal (exclusively)
• Half-life: 17-21 hours
• Monitoring: Generally not required; anti-Xa levels if needed
• No antidote (long half-life problematic)

Dosing [22]:

Contraindication: CrCl below 30 mL/min (accumulation risk)

Advantages: Once daily dosing; no monitoring required; subcutaneous administration; minimal cross-reactivity with HIT antibodies; does not affect INR

Disadvantages: Long half-life (not easily reversible); renal clearance (contraindicated in AKI); off-label use for HIT

Comparison of Alternative Anticoagulants

Transitioning to Oral Anticoagulation

Warfarin

Traditional transition to warfarin requires careful attention to timing [15,20]:

When to start:

• Only after platelet count has recovered to greater than 150 x 10⁹/L
• Patient must be on therapeutic dose alternative anticoagulant
• Never initiate during acute thrombocytopenia phase

How to start:

• Begin with low dose (2-5 mg daily)
• Overlap with parenteral anticoagulant for minimum 5 days
• Continue parenteral anticoagulant until INR therapeutic (2.0-3.0) for 2 consecutive days
• Argatroban falsely elevates INR; check INR 4-6 hours after stopping argatroban

Risk of venous limb gangrene if warfarin started prematurely:

• Depletes protein C/S faster than procoagulant factors
• Creates transient hypercoagulable window
• Combined with HIT-induced thrombin generation → microvascular thrombosis

Direct Oral Anticoagulants (DOACs)

DOACs are increasingly used for HIT transition and offer several advantages [16,17]:

Evidence:

• Retrospective studies and case series support efficacy and safety
• No large RCTs specifically in HIT, but extrapolated from VTE treatment data
• ASH guidelines suggest DOACs as alternative to warfarin for HIT transition

Rivaroxaban [16]:

• 15 mg twice daily for 21 days, then 20 mg once daily
• CrCl greater than 50 mL/min required for full dose
• Can be started once platelet count recovering

Apixaban [17]:

• 10 mg twice daily for 7 days, then 5 mg twice daily
• May be preferred in renal impairment (less renal clearance than rivaroxaban)
• Increasing evidence in HIT patients

Advantages over warfarin:

• No overlap period required (can stop parenteral and start DOAC same day)
• Rapid onset (no concern for protein C depletion)
• No INR monitoring
• Lower venous limb gangrene risk

Disadvantages:

• Limited specific HIT data
• Drug interactions and contraindications apply
• Renal dose adjustments required
• Limited reversal options (although improving)

Duration of Anticoagulation

The duration of anticoagulation after HIT depends on thrombotic complications [5,18]:

Rationale for anticoagulation even without thrombosis:

• Thrombotic risk persists for 30-40 days after HIT diagnosis
• 25-50% of patients will develop thrombosis if inadequately anticoagulated
• Minimum 4 weeks covers the high-risk period

Special Situations

Cardiac Surgery with History of HIT

Patients with prior HIT requiring cardiac surgery with cardiopulmonary bypass present a significant challenge [28]:

If HIT antibodies are no longer detectable (greater than 100 days since HIT):

• Can use heparin intraoperatively for bypass (brief exposure)
• Avoid preoperative and postoperative heparin
• Use alternative anticoagulation for thromboprophylaxis

If HIT antibodies still detectable:

• Avoid heparin entirely
• Bivalirudin for cardiopulmonary bypass (specialized protocol)
• Requires experienced cardiac anesthesia and surgery team

ECMO and Mechanical Circulatory Support

HIT during ECMO is particularly challenging due to the need for continuous anticoagulation [29]:

Argatroban for ECMO:

• Start at lower doses (0.2-0.5 mcg/kg/min)
• Target aPTT or ACT based on institutional protocol
• Monitor for circuit clotting

Bivalirudin for ECMO:

• May be preferred (shorter half-life, proteolytic metabolism)
• Typical dose 0.03-0.1 mg/kg/hr
• Target ACT 180-220 seconds

Renal Replacement Therapy

Hemodialysis in HIT patients [30]:

• Argatroban: No dose adjustment; given as bolus + infusion during dialysis
• Bivalirudin: Significant dose reduction needed (50% or more)
• Fondaparinux: Contraindicated (CrCl below 30 mL/min)
• Citrate anticoagulation: Safe alternative for circuit anticoagulation

CRRT in HIT patients:

• Regional citrate anticoagulation preferred (avoids need for systemic anticoagulation of circuit)
• If systemic anticoagulation required: argatroban or bivalirudin

Pregnancy

HIT in pregnancy is rare but requires special consideration [40]:

• Fondaparinux generally preferred (category B)
• Argatroban and bivalirudin cross placenta (limited data)
• DOACs contraindicated in pregnancy
• Early involvement of maternal-fetal medicine and hematology

---

Prognosis and Outcomes

Natural History Without Treatment

Untreated HIT carries severe consequences [9,27]:

• Thrombosis rate: 25-50% within 30 days
• Mortality: 20-30% (primarily from PE, stroke, limb ischemia)
• Limb loss: 10-20% of those with limb thrombosis
• Residual morbidity: 20-30% with significant disability

Outcomes With Appropriate Treatment

With prompt recognition and appropriate management, outcomes are significantly improved [2,27]:

• Mortality: 5-10%
• Thrombosis (new): 5-10%
• Limb amputation: 3-5%
• Complete platelet recovery: greater than 95% within 7-14 days

Predictors of Poor Outcome

Higher thrombosis risk [9,26]:

• Magnitude of platelet drop greater than 50%
• Delayed diagnosis and treatment initiation
• Inadequate anticoagulation
• Underlying malignancy
• Presence of indwelling catheters
• Cardiac surgery population

Higher mortality risk:

• Arterial thrombosis (stroke, limb ischemia)
• Pulmonary embolism
• Age greater than 65 years
• Underlying sepsis or critical illness
• Venous limb gangrene (warfarin-associated)

Long-Term Considerations

Re-exposure to heparin [41]:

• Generally safe greater than 100 days after HIT (antibodies typically cleared)
• Confirm antibody-negative status before planned re-exposure
• Brief intraoperative exposure (e.g., cardiac surgery) lower risk than prolonged exposure
• Document HIT history clearly in medical record

Recurrent HIT:

• Can occur with heparin re-exposure
• Usually within 5-14 days if antibodies have cleared and re-form
• May be immediate (below 24 hours) if antibodies still present

---

Prevention

Risk Reduction Strategies

Limit heparin exposure duration [1,24]:

• Use LMWH instead of UFH when possible (lower HIT risk)
• Minimize duration of heparin therapy to below 5 days when feasible
• Consider fondaparinux for thromboprophylaxis (very low HIT risk)

Platelet count monitoring [42]:

• Not universally required for all heparin patients
• Higher-risk populations warrant monitoring:
  • Postoperative patients on UFH (cardiac, orthopedic surgery)
  • Medical patients on UFH for greater than 4 days
• Check platelet count every 2-3 days from day 4 to day 14

Education and awareness:

• High index of suspicion in patients with unexplained platelet drop
• Recognize atypical presentations (skin necrosis, thrombosis)
• Prompt calculation of 4Ts score when HIT suspected

Patients with Previous HIT

Documentation [41]:

• Clear documentation of HIT history in medical record
• Alert bracelet or card recommended
• List alternative anticoagulants that were used successfully

Future anticoagulation:

• Avoid heparin when alternatives exist
• If heparin absolutely required (e.g., cardiac surgery):
  • Confirm antibody-negative (greater than 100 days from HIT episode)
  • Minimize exposure duration
  • Consider preoperative plasmapheresis (experimental)
  • Close monitoring for HIT recurrence

---

SAQ Practice Questions

SAQ 1: 4Ts Score and Initial Management

Clinical Scenario: A 67-year-old man is day 8 post-coronary artery bypass grafting. He has been receiving unfractionated heparin 5000 units SC twice daily for DVT prophylaxis. His platelet count was 245 x 10⁹/L preoperatively. Today his platelet count is 98 x 10⁹/L. He has no clinical evidence of bleeding. A right lower limb DVT was identified on Doppler ultrasound performed for new calf swelling.

(a) Calculate the 4Ts score for this patient (4 marks)

(b) Outline your immediate management (6 marks)

---

Model Answer:

(a) 4Ts Score Calculation (4 marks)

Total: 7/8 = High probability of HIT

(b) Immediate Management (6 marks)

Stop all heparin (1 mark):

• Discontinue subcutaneous UFH
• Stop heparin flushes for all IV lines
• Remove heparin-coated catheters if feasible
• Communicate to nursing and pharmacy

Start alternative anticoagulation at therapeutic dose (2 marks):

• Argatroban preferred (patient likely has some hepatic congestion post-cardiac surgery, but renal function typically preserved)
• Start argatroban at 0.5-1.0 mcg/kg/min (lower than package insert due to ICU setting)
• Target aPTT 1.5-3.0 x baseline
• Alternative: Bivalirudin 0.15-0.2 mg/kg/hr

Send diagnostic testing (1 mark):

• PF4/heparin ELISA
• Request functional assay (SRA) if ELISA positive

Additional thrombosis screening (1 mark):

• Although DVT already identified, screen for occult PE given high-risk presentation
• Consider CTPA if any respiratory symptoms

Supportive measures (1 mark):

• Do NOT transfuse platelets (unless life-threatening bleeding)
• Do NOT start warfarin until platelet count greater than 150 x 10⁹/L
• Monitor platelet count daily for recovery
• Ensure DVT appropriately managed (therapeutic anticoagulation, consider IVC filter only if contraindication to anticoagulation, which is not the case here)

---

SAQ 2: Alternative Anticoagulant Selection

Clinical Scenario: A 58-year-old woman with acute kidney injury (creatinine 420 μmol/L, estimated GFR 12 mL/min) and Child-Pugh B cirrhosis develops confirmed HIT while receiving LMWH for DVT treatment. Her current platelet count is 62 x 10⁹/L (from baseline 180 x 10⁹/L). She is hemodynamically stable.

(a) Discuss the challenges in selecting an alternative anticoagulant for this patient (4 marks)

(b) Which agent would you choose and why? Include dosing recommendations (4 marks)

(c) How would you monitor anticoagulation and plan for transition to oral therapy? (2 marks)

---

Model Answer:

(a) Challenges in Alternative Anticoagulant Selection (4 marks)

Renal dysfunction (1 mark):

• Fondaparinux contraindicated (exclusively renal clearance)
• Bivalirudin has 20% renal clearance; significant dose reduction needed
• LMWH contraindicated (already causative agent and renally cleared)

Hepatic dysfunction (1 mark):

• Argatroban is hepatically cleared; half-life significantly prolonged in Child-Pugh B/C cirrhosis
• Standard dosing will result in excessive anticoagulation
• Bleeding risk increased due to impaired coagulation factor synthesis

Combined organ dysfunction (1 mark):

• No single agent has ideal pharmacokinetics
• All options require significant dose adjustment
• Increased bleeding risk from both organ failures
• Close monitoring essential regardless of choice

Monitoring challenges (1 mark):

• aPTT may be unreliable in cirrhosis (baseline prolongation)
• Anti-Xa assays for fondaparinux not applicable here
• Viscoelastic testing (TEG/ROTEM) may be helpful adjunct

(b) Recommended Agent and Dosing (4 marks)

Bivalirudin is the preferred agent in combined hepatic and renal dysfunction (2 marks):

• 80% of metabolism is proteolytic (non-enzymatic); only 20% renal
• Shorter half-life (25 minutes at baseline) than argatroban
• More predictable pharmacokinetics in hepatic disease than argatroban

Dosing (2 marks):

• Starting dose: 0.05-0.08 mg/kg/hr (significantly reduced for renal impairment)
• Do NOT give loading dose in this setting
• Target aPTT 1.5-2.5 x baseline (use ACT if aPTT unreliable)
• Check aPTT/ACT every 2-4 hours initially
• Titrate in small increments based on response

Alternative consideration: Argatroban at 0.25-0.5 mcg/kg/min could be used, but half-life will be significantly prolonged (potentially 4+ hours instead of 45 minutes), making dose titration challenging. Renal failure would not affect argatroban clearance, but the hepatic dysfunction is the limiting factor.

(c) Monitoring and Transition to Oral Therapy (2 marks)

Monitoring (1 mark):

• aPTT every 2-4 hours initially, then every 6-12 hours once stable
• Daily platelet count to monitor for recovery (expect improvement within 5-7 days)
• Watch for bleeding complications given dual organ dysfunction
• Consider viscoelastic testing for global assessment

Transition to oral therapy (1 mark):

• DOACs require caution: Apixaban has lowest renal clearance (~25%), but still needs dose adjustment; rivaroxaban not ideal with CrCl below 30
• Warfarin: INR inherently elevated in cirrhosis; difficult to interpret therapeutic range
• May need prolonged parenteral therapy until platelet recovery and clinical stabilization
• Multidisciplinary discussion with hematology, hepatology, and nephrology recommended
• If dialysis initiated, citrate regional anticoagulation may reduce need for systemic anticoagulation

---

Viva Scenarios

Viva 1: Pathophysiology of HIT

Examiner: Describe the immunological mechanism by which heparin causes thrombocytopenia AND thrombosis in HIT.

Expected Answer Structure:

PF4-Heparin Complex Formation:

• Platelet factor 4 (PF4) is released from platelet alpha-granules during platelet activation
• PF4 is a positively charged chemokine that binds heparin (negatively charged)
• Optimal stoichiometry creates large ultra-large multimolecular complexes
• UFH forms larger complexes than LMWH (explains higher HIT incidence with UFH)

Neoantigen Exposure and Antibody Formation:

• Heparin binding induces conformational change in PF4
• Exposes cryptic epitopes not present on native PF4
• Immune system recognizes these as foreign neoantigens
• IgG antibodies form against PF4/heparin complex (typically day 5-10)

Platelet Activation Mechanism:

• Anti-PF4/heparin IgG binds to complexes on platelet surface
• Fc portion of IgG binds to FcγRIIa receptors on platelets
• Cross-linking of FcγRIIa triggers:
  • Platelet degranulation (releases more PF4 - positive feedback)
  • Phosphatidylserine exposure
  • Release of procoagulant microparticles
  • Thromboxane A2 generation

Why Both Thrombocytopenia AND Thrombosis?:

• Thrombocytopenia: Platelet consumption by activated clotting + splenic clearance of antibody-coated platelets
• Thrombosis: Massive thrombin generation from procoagulant microparticles + endothelial/monocyte tissue factor expression
• Platelet count drop reflects intensity of prothrombotic process

Endothelial and Monocyte Involvement:

• PF4 binds to heparan sulfate on endothelium
• HIT antibodies bind → endothelial activation → tissue factor expression
• Monocyte FcγRIIa binding → monocyte tissue factor → systemic hypercoagulability

---

Viva 2: 4Ts Score Interpretation

Examiner: A patient has a 4Ts score of 5. Explain how you would interpret this result and what your next steps would be.

Expected Answer Structure:

Interpretation of Score 5:

• Score 4-5 indicates INTERMEDIATE probability of HIT
• Pre-test probability approximately 10-20%
• NPV approximately 80-90%; PPV approximately 10-20%
• Cannot confidently rule in or rule out HIT

Clinical Decision Point:

• This is the most challenging clinical scenario
• Must balance risks of:
  • "Continued heparin (if not HIT): risk of thrombosis if HIT and heparin continues"
  • "Alternative anticoagulation (if not HIT): increased bleeding risk, cost, monitoring burden"
  • "No anticoagulation: unacceptable in most scenarios"

Recommended Approach:

1. Stop heparin and initiate alternative anticoagulation: The risk of thrombosis if this IS HIT and heparin continues outweighs the risks of alternative anticoagulation
2. Send immunoassay (ELISA): Urgent processing if available
3. Monitor platelet count: Expect recovery within 5-7 days if HIT
4. Screen for occult thrombosis: Doppler ultrasound of lower extremities

Based on ELISA Result:

• Negative (OD below 0.4): HIT effectively excluded; can resume heparin if clinically indicated
• Weakly positive (OD 0.4-1.0): Still uncertain; request functional assay (SRA); continue alternative anticoagulation pending result
• Moderate positive (OD 1.0-2.0): HIT probable; request functional assay for confirmation; continue alternative anticoagulation
• Strongly positive (OD ≥2.0): HIT highly likely; continue alternative anticoagulation; functional assay optional

Key Teaching Point: Intermediate 4Ts scores require laboratory testing to guide definitive management. Empiric treatment is appropriate while awaiting results given the potentially catastrophic consequences of missed HIT.

---

Viva 3: Argatroban Dosing in ICU

Examiner: Why is the package insert dose of argatroban (2 mcg/kg/min) often inappropriate for ICU patients? What dose would you start?

Expected Answer Structure:

Reasons for Lower Dosing in ICU:

Hepatic dysfunction/congestion:

• Argatroban is hepatically cleared (CYP3A4)
• Right heart failure → hepatic congestion → reduced hepatic blood flow
• Cardiogenic shock, septic shock reduce hepatic clearance
• Half-life increases from 45 minutes to 2-4+ hours

Critical illness physiology:

• Reduced cardiac output → reduced hepatic perfusion
• Multiple organ dysfunction syndrome affects clearance
• Post-cardiac surgery patients have reduced hepatic function
• Sepsis affects drug metabolism unpredictably

Protein binding:

• Argatroban is ~54% protein bound
• Critical illness → hypoalbuminemia → increased free drug fraction
• Results in greater effect for same dose

Evidence base:

• Studies show ICU patients require 50-75% dose reduction
• Using package insert dose leads to excessive anticoagulation
• Increased bleeding complications with standard dosing

Recommended ICU Dosing:

Titration Approach:

• Check aPTT 2 hours after initiation
• Target aPTT 1.5-3.0 x baseline (or 46-70 seconds absolute)
• Adjust in 0.25 mcg/kg/min increments
• Recheck aPTT 2 hours after each adjustment
• Once stable, can check every 6-12 hours

---

Viva 4: Warfarin Contraindication in Acute HIT

Examiner: Why is warfarin contraindicated in the acute phase of HIT? What happens if it has already been started?

Expected Answer Structure:

Mechanism of Harm:

Protein C/S depletion:

• Warfarin inhibits vitamin K-dependent factors (II, VII, IX, X)
• Also inhibits anticoagulant proteins C and S
• Half-lives differ significantly:
  • "Protein C: 6-8 hours"
  • "Protein S: 30-40 hours"
  • "Factor VII: 4-6 hours"
  • "Factor II (prothrombin): 60-72 hours"

Transient hypercoagulable state:

• Anticoagulant proteins (C, S) depleted faster than procoagulants
• Creates paradoxical hypercoagulable window during first 3-5 days
• Normally balanced by continued heparin anticoagulation

Compounded by HIT:

• HIT already causes massive thrombin generation
• Adding warfarin's transient hypercoagulable state = catastrophic
• Tips balance further toward thrombosis
• Results in microvascular thrombosis of small vessels

Venous Limb Gangrene:

• Classic complication of warfarin initiated during acute HIT
• Progressive, symmetric limb cyanosis
• Microvascular thrombosis in venous circulation
• Often at extremities (toes, fingers, limbs)
• INR often supratherapeutic (greater than 3.0) at time of onset
• May progress to irreversible gangrene requiring amputation

Management if Warfarin Already Started:

1. Stop warfarin immediately
2. Give vitamin K to reverse warfarin effect:
   • Vitamin K1 (phytomenadione) 2.5-10 mg IV/PO
   • Goal: restore vitamin K-dependent proteins
3. Continue/start alternative anticoagulation (argatroban/bivalirudin)
4. Monitor for limb ischemia
5. Do NOT restart warfarin until:
   • Platelet count greater than 150 x 10⁹/L
   • On therapeutic alternative anticoagulation
   • No evidence of progressive thrombosis

When to Safely Start Warfarin:

• Platelet count recovered to greater than 150 x 10⁹/L
• Therapeutic on alternative anticoagulant
• Start at low dose (2-5 mg daily)
• Overlap with parenteral agent for minimum 5 days
• Continue until INR therapeutic (2.0-3.0) for 2 consecutive days

Alternative Approach - DOACs:

• Consider rivaroxaban or apixaban instead of warfarin
• Can be started once platelet count recovering
• No overlap period required
• No protein C depletion concerns
• Growing evidence supports DOAC use in HIT

---

Differential Diagnosis

Other Causes of Thrombocytopenia in ICU

The differential diagnosis of thrombocytopenia in critically ill patients is extensive. HIT must be distinguished from other common causes of platelet drop:

Sepsis-Related Thrombocytopenia [43]:

• Most common cause of thrombocytopenia in ICU (25-50%)
• Mechanism: bone marrow suppression, consumption, splenic sequestration
• Usually correlates with severity of sepsis
• Platelet count typically recovers with infection control
• Key differentiator: timing (septic thrombocytopenia begins at admission; HIT typically day 5-14)

Disseminated Intravascular Coagulation (DIC) [44]:

• Consumptive coagulopathy with thrombocytopenia
• Laboratory: elevated D-dimer, prolonged PT/aPTT, decreased fibrinogen
• Associated with underlying trigger (sepsis, malignancy, trauma, obstetric complications)
• Microangiopathic hemolytic anemia may be present
• Can coexist with HIT (complicates diagnosis)

Drug-Induced Thrombocytopenia (Non-HIT) [45]:

• Many ICU drugs can cause thrombocytopenia: vancomycin, piperacillin-tazobactam, linezolid, quinidine
• Usually immune-mediated or dose-dependent marrow suppression
• Timing variable (can be immediate or delayed)
• Diagnosis: temporal relationship, resolution upon drug withdrawal

Thrombotic Microangiopathies (TTP/HUS/aHUS) [46]:

• Microangiopathic hemolytic anemia (schistocytes, elevated LDH, low haptoglobin)
• Thrombocytopenia typically more severe than HIT (below 20 x 10⁹/L common)
• ADAMTS13 activity below 10% diagnostic for TTP
• Complement-mediated in atypical HUS
• Renal involvement prominent in HUS

Heparin-Independent Anti-PF4 Disorders [37]:

• Vaccine-induced immune thrombocytopenia and thrombosis (VITT)
• Spontaneous HIT syndrome (very rare)
• Similar pathophysiology to HIT but triggered by non-heparin antigens
• Anti-PF4 antibodies present; may activate in absence of heparin

Post-Cardiac Surgery Thrombocytopenia [28]:

• Expected platelet drop after cardiopulmonary bypass
• Usually nadir day 1-3, recovery by day 5-7
• Due to hemodilution, consumption, mechanical damage
• HIT should be considered if platelet count drops greater than 50% from post-bypass nadir OR fails to recover by day 5

Hemodilution:

• Large volume resuscitation dilutes platelet count
• Common in massive transfusion, fluid resuscitation
• Corrects with cessation of fluid therapy
• Calculate corrected platelet count if concerned

Liver Disease-Associated:

• Hypersplenism causes platelet sequestration
• Decreased thrombopoietin production
• Usually chronic; baseline low platelets
• Acute drop from baseline should still prompt HIT consideration

Distinguishing Features of HIT

HIT Mimics in Specific Clinical Scenarios

Cardiac Surgery:

• Postoperative HIT incidence 1-3%
• Must distinguish from expected post-bypass platelet drop
• Clues: persistent decline after day 5, failure to recover, new thrombosis

ECMO:

• ECMO consumption causes ongoing thrombocytopenia
• Circuit thrombosis may be HIT or non-HIT
• Higher threshold for HIT testing given prolonged heparin exposure

COVID-19:

• SARS-CoV-2 infection causes thrombocytopenia and thrombosis
• May mimic HIT clinically
• COVID-19 patients may have positive PF4 antibodies without HIT
• Functional assays help distinguish

---

ICU-Specific Considerations

Challenges in the ICU Setting

Multiple Causes of Thrombocytopenia: ICU patients frequently have multiple simultaneous reasons for thrombocytopenia, making HIT diagnosis challenging:

• Sepsis, DIC, and HIT can coexist
• Calculation of 4Ts score complicated by "oTher causes"
• Often requires empiric treatment while awaiting confirmatory testing

Organ Dysfunction Effects on Treatment:

Monitoring Difficulties:

• Baseline aPTT often abnormal in critical illness
• DIC causes prolonged clotting times
• Alternative monitoring strategies may be needed:
  • Chromogenic anti-Xa assays for fondaparinux
  • Ecarin clotting time for DTIs (if available)
  • ACT for bivalirudin (especially in ECMO)

HIT During Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) [30]:

• Regional citrate anticoagulation preferred (avoids systemic anticoagulation)
• If systemic anticoagulation required for HIT treatment:
  • "Argatroban: no dose adjustment for CRRT; provide usual HIT dosing"
  • "Bivalirudin: significantly cleared by CRRT; may need higher doses"
• Monitor for circuit clotting as indicator of anticoagulation adequacy

Intermittent Hemodialysis [30]:

• Argatroban bolus (250 mcg/kg) + infusion during dialysis
• Continue baseline infusion between sessions
• Citrate anticoagulation alternative for circuit only

HIT During ECMO

Incidence and Challenges [29]:

• Prolonged heparin exposure increases HIT risk
• Diagnosis complicated by ECMO-related thrombocytopenia
• Circuit thrombosis has broad differential

Anticoagulation Options:

Practical Considerations:

• Bivalirudin often preferred (shorter half-life, less INR interference)
• Higher circuit clotting rates may be observed with DTIs vs heparin
• Close circuit surveillance essential
• Involve perfusionist and ECMO specialist in anticoagulation decisions

Post-Operative Cardiac Surgery HIT

Challenges in Diagnosis [28]:

• Expected post-bypass thrombocytopenia (nadir day 1-3)
• Multiple other causes: hemodilution, sepsis, drug-induced
• Higher false-positive rate on ELISA due to PF4 release during bypass
• Need high clinical suspicion if platelet count fails to recover by day 5

Management Considerations:

• Early involvement of hematology
• Lower threshold for alternative anticoagulation if:
  • Persistent decline in platelet count after day 5
  • New thrombosis (stroke, graft occlusion, limb ischemia)
  • Skin necrosis at heparin injection sites
• May need to delay discharge pending HIT workup

Platelet Transfusion in HIT

General Principle: Avoid platelet transfusion in HIT unless life-threatening bleeding [1]:

• Theoretical concern: transfused platelets "fuel the fire" by providing more targets for activation
• No RCT data; based on theoretical risk and case reports
• Platelet transfusion should NOT be withheld if:
  • Active life-threatening bleeding
  • Urgent surgical procedure with high bleeding risk
  • Profound thrombocytopenia (below 10 x 10⁹/L) with mucosal bleeding

If Platelet Transfusion Required:

• Ensure patient is on therapeutic alternative anticoagulation
• Transfuse the minimum dose necessary
• Monitor closely for new thrombotic events
• Document clinical indication clearly

---

Pharmacology Summary Tables

Alternative Anticoagulant Dosing Quick Reference

Argatroban Dosing [13,14]:

Bivalirudin Dosing [21]:

Fondaparinux Dosing [22]:

Transition to Oral Anticoagulation

Warfarin Transition [15]:

• Wait until platelets greater than 150 x 10⁹/L
• Start warfarin 2-5 mg daily
• Overlap parenteral anticoagulant for ≥5 days
• Continue parenteral until INR 2.0-3.0 for 2 consecutive days
• Argatroban increases INR: check INR 4-6 hours after stopping argatroban

DOAC Transition [16,17]:

---

References

1. Greinacher A. Heparin-Induced Thrombocytopenia. N Engl J Med. 2015;373(3):252-261. PMID: 26176382

2. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest. 2004;126(3 Suppl):311S-337S. PMID: 15383477

3. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. Thromb Haemost. 2016;116(5):813-822. PMID: 27488143

4. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759-765. PMID: 16634744

5. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392. PMID: 30482768

6. Arepally GM. Heparin-induced thrombocytopenia. Blood. 2017;129(21):2864-2872. PMID: 28315165

7. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120(20):4160-4167. PMID: 22990018

8. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344(17):1286-1292. PMID: 11320387

9. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330-1335. PMID: 7715641

10. Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008;6(8):1304-1312. PMID: 18503629

11. Warkentin TE, Greinacher A, Gruel Y, Aster RH, Chong BH. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost. 2011;9(12):2498-2500. PMID: 21952182

12. Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2004;2(12):2133-2137. PMID: 15613018

13. Link A, Girndt M, Selejan S, Mathes A, Böhm M, Rensing H. Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med. 2009;37(1):105-110. PMID: 19050625

14. Beiderlinden M, Treschan TA, Görlinger K, Peters J. Argatroban anticoagulation in critically ill patients. Ann Pharmacother. 2007;41(5):749-754. PMID: 17456541

15. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):340S-380S. PMID: 18574270

16. Linkins LA, Warkentin TE, Pai M, et al. Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study. J Thromb Haemost. 2016;14(6):1206-1210. PMID: 27061249

17. Skelley JW, Kyle JA, Roberts RA. Novel oral anticoagulants for heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2016;42(2):172-178. PMID: 26747469

18. Warkentin TE. Heparin-induced thrombocytopenia: diagnosis and management. Circulation. 2004;110(18):e454-458. PMID: 15520330

19. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg. 2003;76(6):2121-2131. PMID: 14667666

20. Warkentin TE, Eikelboom JW, Hayward CP, et al. Warfarin-induced limb gangrene associated with a markedly elevated international normalized ratio and presence of the lupus anticoagulant. Arch Intern Med. 1997;157(10):1094-1100. PMID: 9164376

21. Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg. 2007;83(2):572-577. PMID: 17257989

22. Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost. 2008;99(1):208-214. PMID: 18217155

23. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 1993;69(4):344-350. PMID: 8497847

24. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8):2710-2715. PMID: 15985543

25. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96(5):1703-1708. PMID: 10961867

26. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003;163(20):2518-2524. PMID: 14609790

27. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163(15):1849-1856. PMID: 12912722

28. Potzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med. 2000;343(7):515. PMID: 10970097

29. Prechel MM, Walenga JM. Heparin-induced thrombocytopenia: an update. Semin Thromb Hemost. 2012;38(5):483-496. PMID: 22566149

30. Murray PT, Reddy BV, Grossman EJ, et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int. 2004;66(6):2446-2453. PMID: 15569339

31. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood. 1988;72(3):925-930. PMID: 2458145

32. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med. 1987;316(10):581-589. PMID: 3807952

33. Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84(11):3691-3699. PMID: 7949126

34. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994;93(1):81-88. PMID: 8282824

35. Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood. 2006;107(6):2346-2353. PMID: 16304054

36. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001;135(7):502-506. PMID: 11578152

37. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021;384(22):2092-2101. PMID: 33835769

38. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med. 2004;164(4):361-369. PMID: 14980986

39. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med. 2007;356(25):2653-2655. PMID: 17582082

40. Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost. 2005;93(1):63-69. PMID: 15630492

41. Warkentin TE, Anderson JA. How I treat patients with a history of heparin-induced thrombocytopenia. Blood. 2016;128(3):348-359. PMID: 27114458

42. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005;106(12):3791-3796. PMID: 16109780

43. Vanderschueren S, De Weerdt A, Malbrain M, et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med. 2000;28(6):1871-1876. PMID: 10890635

44. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341(8):586-592. PMID: 10451465

45. Arnold DM, Kukaswadia S, Nazi I, et al. A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. J Thromb Haemost. 2013;11(1):169-176. PMID: 23140172

46. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323-335. PMID: 22624596